Enhancement of endotoxin-induced vascular hyporeactivity to phenylephrine in the thoracic aortas of Mg-deficient rats ex vivo

Life Sci. 2003 Oct 10;73(21):2713-26. doi: 10.1016/s0024-3205(03)00613-1.

Abstract

Since endotoxin lethality is enhanced by Mg deficiency in animals, we determined whether endotoxin-induced vascular hyporeactivity to phenylephrine (PE) is enhanced in Mg-deficient rats. Normal and Mg-deficient adult male Wistar rats were injected with Escherichia coli 011: B4 lipopolysaccharide (1 or 5 mg/kg, i.p.). Six h later, rings prepared from their thoracic aortas showed severe hyporeactivity to PE. This was more pronounced in the Mg-deficient rats, and was reversed by in vitro treatment with a highly selective inducible nitric oxide (NO) synthase inhibitor, 1400 W, or a highly selective soluble guanylyl cyclase inhibitor, ODQ. However, reversal required high doses of both inhibitors in Mg-deficient rats. Endotoxemia for 6 h was associated with elevated serum interleukin (IL)-1beta and tumor necrosis factor (TNF)-alpha levels, and strong TNF receptor mRNA expression in the abdominal aortas, which were significantly greater in the Mg-deficient rats. Treatment of the thoracic aortas, isolated from control and Mg-deficient rats before endotoxic challenge, with IL-1beta or TNF-alpha for 6 h in vitro caused hyporeactivity to PE, but its severity did not differ significantly between the two groups. These results suggest that high serum IL-1beta and TNF-alpha levels, and increased TNF receptor production in the vascular tissue, contribute to vascular hyporeactivity to PE in endotoxemia, and to its enhancement in Mg-deficient rats, via NO/cGMP signaling.

MeSH terms

  • Amidines / pharmacology
  • Animals
  • Aorta, Thoracic / drug effects*
  • Benzylamines / pharmacology
  • Diet
  • Dose-Response Relationship, Drug
  • Enzyme Inhibitors / pharmacology
  • Escherichia coli / immunology
  • In Vitro Techniques
  • Injections, Intraperitoneal
  • Interleukin-1 / pharmacology
  • Lipopolysaccharides / administration & dosage
  • Lipopolysaccharides / pharmacology*
  • Magnesium Deficiency / metabolism*
  • Male
  • Muscle Contraction / drug effects
  • Muscle, Smooth, Vascular / cytology
  • Muscle, Smooth, Vascular / drug effects*
  • Oxadiazoles / pharmacology
  • Phenylephrine / pharmacology*
  • Quinoxalines / pharmacology
  • RNA, Messenger / metabolism
  • Rats
  • Rats, Wistar
  • Receptors, Tumor Necrosis Factor / genetics
  • Receptors, Tumor Necrosis Factor / metabolism
  • Tumor Necrosis Factor-alpha / pharmacology

Substances

  • 1H-(1,2,4)oxadiazolo(4,3-a)quinoxalin-1-one
  • Amidines
  • Benzylamines
  • Enzyme Inhibitors
  • Interleukin-1
  • Lipopolysaccharides
  • N-(3-(aminomethyl)benzyl)acetamidine
  • Oxadiazoles
  • Quinoxalines
  • RNA, Messenger
  • Receptors, Tumor Necrosis Factor
  • Tumor Necrosis Factor-alpha
  • Phenylephrine